Lacidipine
Lacidipine (Lacipil, Motens) is a L-type calcium channel blocker.Lacidipine, a novel third-generation dihydropyridine calcium channel blocker, has been demonstrated effective for hypertension. lacidipine protects HKCs against apoptosis induced by ATP depl. (In Vitro) :Lacidipine (0.01-100 μM; 24 h) inhibits HKCs proliferation in vitro in a concentration-dependent manner.Lacidipine (0.01-100 μM; 24 h) protects HKCs against apoptosis induced by ATP depletion and recovery by regulating the caspase-3 pathway. (In Vivo) :Lacidipine (0.3, 1.0, 3.0 mg/kg; p.o.; single daily for 10 weeks) shows anti-atherogenic effects in the apoE-deficient mouse, and reduces plasma endothelin concentrations.
Product Specifications
CAS Number
103890-78-4
Product Name Alternative
Lacidipine | Lacipil | Lacimen | Motens | GR 43659 X
Field of Research
Pharmacology & Drug Discovery
Purity
>98% (HPLC)
Solubility
Ethanol: 22 mg/mL (48.29 mM) ; DMSO: 91 mg/mL (199.76 mM)
Smiles
O=C (C1=C (C) NC (C) =C (C (OCC) =O) C1C2=CC=CC=C2/C=C/C (OC (C) (C) C) =O) OCC
Molecular Formula
C26H33NO6
Molecular Weight
455.54
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
Diethyl (E) -4- (2- (3- (tert-butoxy) -3-oxoprop-1-en-1-yl) phenyl) -2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human CDCA2 sgRNA gene knockout kit - Lentiviral human CDCA2 sgRNA gene knockout kit (100)
NRIP2, ID (NRIP2, Nuclear receptor-interacting protein 2) (MaxLight 650) discontinued